Now showing items 1-1 of 1
The selective jak1/3-inhibitor r507 mitigates obliterative airway disease both with systemic administration and aerosol inhalation
(Ovid Technologies (Wolters Kluwer Health), 2016-05-01)
Background. The efficacy of selective Janus kinase 1/3 inhibitor R507 to prevent obliterative airway disease was analyzed in preclinical airway transplantationmodels. Methods. Orthotopic trachea transplantations were ...